Related Experiment Video

Updated: Jun 12, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Improving glycaemic control in children and adolescents: which aspects of therapy really matter?

T C Skinner1, F J Cameron

  • 1Combined Universities Centre for Rural Health, Geraldton, Western Australia, Australia.

Diabetic Medicine : a Journal of the British Diabetic Association
|June 12, 2010
PubMed

Insights

For pediatric Type 1 diabetes, patient support, team cohesion, and goal setting are crucial for improving glycemic control (HbA1c). Technological advancements alone offer limited benefits without these foundational elements.

Area of Science:

  • Pediatric Endocrinology
  • Diabetes Management
  • Clinical Psychology in Healthcare

Background:

  • Intensive therapy in pediatric diabetes has shifted towards a pharmaco-technological focus.
  • This shift may neglect crucial aspects like goal-setting and psychosocial support.
  • The Diabetes Control and Complications Trial (DCCT) era emphasized comprehensive care.

Purpose of the Study:

  • To identify patient subgroups that benefit most from intensive therapy regarding glycemic control (HbA1c).
  • To review the impact of insulin types and delivery systems on glycemic control.
  • To analyze the influence of patient support, care philosophy, goal setting, and team dynamics on HbA1c.

Main Methods:

  • Literature review of controlled trials and observational data.
  • Analysis of studies on insulin therapy and delivery systems.
  • Synthesis of research on psychosocial factors and team dynamics in diabetes care.

Main Results:

  • Patient support, team cohesion, and goal setting are primary drivers of improved glycemic control in pediatric Type 1 diabetes.
  • Isolated focus on pharmaco-technology yields limited glycemic benefits in this population.
  • Benefits of insulin types and regimens are maximized after addressing core support and goal-setting issues.

Conclusions:

  • A hierarchical approach to pediatric diabetes care is essential, prioritizing psychosocial and team-based factors.
  • Comprehensive care, including strong patient support and clear goals, is more effective than technology alone.
  • Future interventions should integrate technological advancements with fundamental aspects of patient and team support for optimal outcomes.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...